These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 10635874)

  • 1. [Anti-PM-Scl antibody].
    Takasaki Y
    Nihon Rinsho; 1999 Nov; 57 Suppl():428-30. PubMed ID: 10635874
    [No Abstract]   [Full Text] [Related]  

  • 2. PM1-Alpha ELISA: the assay of choice for the detection of anti-PM/Scl autoantibodies?
    Mahler M; Fritzler MJ
    Autoimmun Rev; 2009 Mar; 8(5):373-8. PubMed ID: 19103309
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PM-Scl-75 is the main autoantigen in patients with the polymyositis/scleroderma overlap syndrome.
    Raijmakers R; Renz M; Wiemann C; Egberts WV; Seelig HP; van Venrooij WJ; Pruijn GJ
    Arthritis Rheum; 2004 Feb; 50(2):565-9. PubMed ID: 14872500
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Immunologic tests: Anti-polymyositis-scleroderma (PM-Scl) antibody].
    Takasaki Y
    Nihon Rinsho; 2005 Jul; 63 Suppl 7():502-4. PubMed ID: 16111314
    [No Abstract]   [Full Text] [Related]  

  • 5. Case 26-2001: scleroderma renal crisis and polymyositis.
    Selva O'Callaghan A; Labrador Horrillo M; Vilardell Tarrés M
    N Engl J Med; 2002 Jun; 346(24):1916-8; author reply 1916-8. PubMed ID: 12063382
    [No Abstract]   [Full Text] [Related]  

  • 6. Autoantibodies directed to novel components of the PM/Scl complex, the human exosome.
    Brouwer R; Vree Egberts WT; Hengstman GJ; Raijmakers R; van Engelen BG; Seelig HP; Renz M; Mierau R; Genth E; Pruijn GJ; van Venrooij WJ
    Arthritis Res; 2002; 4(2):134-8. PubMed ID: 11879549
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel aspects of autoantibodies to the PM/Scl complex: clinical, genetic and diagnostic insights.
    Mahler M; Raijmakers R
    Autoimmun Rev; 2007 Aug; 6(7):432-7. PubMed ID: 17643929
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antibodies to fibrillarin, PM-Scl and RNA polymerase III detected by ELISA assays in patients with systemic sclerosis.
    Villalta D; Morozzi G; Tampoia M; Alpini C; Brusca I; Salgarolo V; Papisch W; Bizzaro N
    Clin Chim Acta; 2010 May; 411(9-10):710-3. PubMed ID: 20138166
    [TBL] [Abstract][Full Text] [Related]  

  • 9. C1D is a major autoantibody target in patients with the polymyositis-scleroderma overlap syndrome.
    Schilders G; Egberts WV; Raijmakers R; Pruijn GJ
    Arthritis Rheum; 2007 Jul; 56(7):2449-54. PubMed ID: 17599775
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Anti-Ki/PA28gamma antibody].
    Okano T; Satoh M; Akizuki M
    Nihon Rinsho; 2010 Jun; 68 Suppl 6():569-71. PubMed ID: 20942131
    [No Abstract]   [Full Text] [Related]  

  • 11. Anti-PM/Scl autoantibodies in patients without clinical polymyositis or scleroderma.
    Schnitz W; Taylor-Albert E; Targoff IN; Reichlin M; Scofield RH
    J Rheumatol; 1996 Oct; 23(10):1729-33. PubMed ID: 8895149
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Anti-Ku antibodies].
    Suwa A; Mimori T
    Nihon Rinsho; 1999 Nov; 57 Suppl():450-2. PubMed ID: 10635880
    [No Abstract]   [Full Text] [Related]  

  • 13. The human exosome: an autoantigenic complex of exoribonucleases in myositis and scleroderma.
    Brouwer R; Pruijn GJ; van Venrooij WJ
    Arthritis Res; 2001; 3(2):102-6. PubMed ID: 11178117
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical evaluation of autoantibodies to a novel PM/Scl peptide antigen.
    Mahler M; Raijmakers R; Dähnrich C; Blüthner M; Fritzler MJ
    Arthritis Res Ther; 2005; 7(3):R704-13. PubMed ID: 15899056
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Interstitial lung manifestations in systemic scleroderma. Correlation between alveolitis, autoantibodies and clinical manifestations].
    Witt C; Hiepe F; Brenke A; Romberg B; Apostoloff E
    Z Arztl Fortbild (Jena); 1994 Nov; 88(11):867-71. PubMed ID: 7839707
    [No Abstract]   [Full Text] [Related]  

  • 16. Immunolocalization and partial characterization of a nucleolar autoantigen (PM-Scl) associated with polymyositis/scleroderma overlap syndromes.
    Reimer G; Scheer U; Peters JM; Tan EM
    J Immunol; 1986 Dec; 137(12):3802-8. PubMed ID: 3537125
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The Scl-70 antibody and its clinical significance].
    Kühn G; Jarzabek-Chorzelska M; Blaszczyk M; Kolacinska-Strasz Z; Chorzelski TP; Jablonska S
    Dermatol Monatsschr; 1989; 175(3):133-47. PubMed ID: 2653887
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A juvenile case of overlap syndrome of systemic lupus erythematosus and polymyositis, later accompanied by systemic sclerosis with the development of anti-Scl 70 and anti-Ku antibodies.
    Nitta Y; Muramatsu M
    Pediatr Dermatol; 2000; 17(5):381-3. PubMed ID: 11085667
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [PM-Scl antibody positive systemic sclerosis associated with inclusion-body myositis].
    Kim S; Genth E; Krieg T; Hunzelmann N
    Z Rheumatol; 2005 Oct; 64(7):499-502. PubMed ID: 16244833
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The changing landscape of the clinical value of the PM/Scl autoantibody system.
    Mahler M; Fritzler MJ
    Arthritis Res Ther; 2009; 11(2):106. PubMed ID: 19351430
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.